meningococcal group-B vaccine (rDNA, component, adsorbed) · Medicine question

Can people receiving eculizumab remain at increased risk of invasive meningococcal group B disease after Bexsero vaccination?

Name: Can people receiving eculizumab remain at increased risk of invasive meningococcal group B disease after Bexsero vaccination?
Published: 2026-11-08T01:57:01.643Z

iatroX medicinesPublished 8 November 2026

The answer

Answer

Yes, people receiving eculizumab remain at increased risk of invasive meningococcal group B disease even if they develop antibodies following Bexsero vaccination.

Sources for this answer

Bexsero Meningococcal Group B vaccine for injection in pre-filled syringeGlaxoSmithKline UK · emc · SmPC §4.4 Special warnings and precautions for use · Version 25Document updated 20 March 2025

Sources checked 8 November 2026

loading page…

Answer

Sources for this answer

Answer

Sources for this answer

More questions about meningococcal group-B vaccine (rDNA, component, adsorbed)